Asian Market Insights: Penny Stocks To Watch In August 2026

As we navigate the diverse landscape of Asian markets, investors are keenly observing how global economic shifts and regional developments influence market dynamics. Penny stocks, a term that may seem outdated but remains relevant, often refer to smaller or newer companies offering growth opportunities at lower price points. When these stocks are supported by strong financial health and solid fundamentals, they can present an appealing mix of affordability and potential upside for investors seeking hidden gems in the market.

Here's a peek at a few of the choices from the screener.

Trigiant Group (SEHK:1300)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Trigiant Group Limited is an investment holding company that manufactures and sells feeder cables, optical fiber cables, flame-retardant flexible cables, and other accessories for mobile communications and telecommunication equipment in China, with a market cap of HK$2.78 billion.

Operations: The company's revenue is primarily derived from its Feeder Cable Series at CN¥1.11 billion, Flame-Retardant Flexible Cable Series at CN¥1.18 billion, fibre cable series and related products at CN¥302.07 million, and New-Type Electronic Components at CN¥137.37 million.

Market Cap: HK$2.78B

Trigiant Group, with a market cap of HK$2.78 billion, continues to derive significant revenue from its key product lines including the Feeder Cable Series (CN¥1.11 billion) and Flame-Retardant Flexible Cable Series (CN¥1.18 billion). The company recently secured a substantial contract with China Mobile for power cable products valued at approximately RMB 2.65 billion, signaling robust demand in AI data center infrastructure development. Despite an increase in weekly volatility to 21%, Trigiant maintains satisfactory debt levels and well-covered interest payments, supported by experienced management and board members guiding strategic investments in the burgeoning AIDC sector.

• Unlock comprehensive insights into our analysis of Trigiant Group stock in this financial health report.
• Examine Trigiant Group's past performance report to understand how it has performed in prior years.

HighTide Therapeutics (SEHK:2511)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: HighTide Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for chronic metabolic and liver diseases in Mainland China, with a market cap of HK$1.82 billion.

Operations: HighTide Therapeutics, Inc. has not reported any revenue segments.

Market Cap: HK$1.82B

HighTide Therapeutics, Inc., with a market cap of HK$1.82 billion, is a pre-revenue biopharmaceutical company focused on chronic metabolic and liver diseases in Mainland China. Despite its unprofitability, the company has reduced losses by 6.9% annually over the past five years and boasts sufficient cash runway for over three years based on current free cash flow trends. HighTide's financial stability is bolstered by short-term assets (CN¥532.2 million) that surpass both short-term (CN¥98.3 million) and long-term liabilities (CN¥88.4 million), alongside an experienced board averaging 3.5 years in tenure without significant shareholder dilution recently.

• Jump into the full analysis health report here for a deeper understanding of HighTide Therapeutics.
• Review our historical performance report to gain insights into HighTide Therapeutics' track record.

Star Plus Legend Holdings (SEHK:6683)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Star Plus Legend Holdings Limited, with a market cap of HK$4.24 billion, is an investment holding company involved in retail and IP creation and operation businesses in the People's Republic of China.

Operations: The company generates revenue from its New Retail segment, amounting to CN¥316.32 million, and its IP Creation and Operation segment, which brings in CN¥156.06 million.

Market Cap: HK$4.24B

Star Plus Legend Holdings Limited, with a market cap of HK$4.24 billion, operates in the retail and IP creation sectors in China. Despite being unprofitable and experiencing a 27% annual decline in earnings over five years, the company maintains financial stability with CN¥1.6 billion in short-term assets exceeding its liabilities. A recent strategic partnership with Park Ha Biological Technology aims to innovate the beauty sector through AI-driven solutions like smart skincare products, potentially enhancing their business model. The management team is considered experienced, having an average tenure of 4.9 years without significant shareholder dilution recently.

• Get an in-depth perspective on Star Plus Legend Holdings' performance by reading our balance sheet health report here.
• Understand Star Plus Legend Holdings' track record by examining our performance history report.

Where To Now?

• Access the full spectrum of 1,051 Asian Penny Stocks by clicking on this link.
• Ready For A Different Approach? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com